Key feature: TB-500 was developed as a research compound to study Thymosin Beta-4-related mechanisms without producing the full-length protein, which is more complex to manufacture
The legitimate ones are
Zandiyeh S, Kalantari H, Fakhri A, Nikkhah M, Janani BJ, Sabbaghian M
doi: 10.3389/fphar.2022.1033069 Received 31 August 2022 Accepted 21 November 2022 Published 02 December 2022 Volume 13 - 2022 Edited by Thomas Brzozowski, Jagiellonian University Medical College, Poland Reviewed by Jason Bush, Brandon University, Canada Qi Wang, Fujian Academy of Agricultural Sciences, China Hongtao Liu, Hubei University of Chinese Medicine, China Hao Zhong, Zhejiang University of Technology, China Updates Copyright 2022 Li, Li, Li, Chen and Liu
Jzwiak M et al., Pharmaceuticals (Basel) (2025) Review of multifunctional properties and experimental applications of BPC-157